Welcome to our dedicated page for BIOTRICITY SEC filings (Ticker: BTCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotricity Inc. filings document a Nevada medical technology issuer focused on remote cardiac monitoring, diagnostic and post-diagnostic solutions, and Technology-as-a-Service healthcare workflows. Form 8-K reports include financial-results releases and material definitive agreements tied to the company’s operating updates and capital structure.
The filing record also covers registration-statement disclosures, common stock, warrants, options and preferred-stock terms. Recent capital-structure disclosures include exchange agreements, a certificate of designation for Series C Preferred Stock, voting rights and conversion mechanics, alongside governance and risk information relevant to the company’s public reporting obligations.
Biotricity Inc. (BTCY) reported higher quarterly revenue but remains highly leveraged and subject to going concern risk for the three months ended June 30, 2026. Revenue rose to $4.28 million from $3.87 million a year earlier, driven mainly by technology fees of $4.17 million. Gross profit increased to $3.53 million, while operating income was modest at $158,068.
After heavy interest, accretion and derivative-related expenses, the company recorded a net loss attributable to common stockholders of $1.07 million versus $0.75 million in the prior-year quarter, and a basic and diluted loss per share of $0.046. Operating cash flow improved to a positive $507,227, but cash on hand was only $466,503 at quarter-end.
The balance sheet is highly strained: total assets were $6.02 million against total liabilities of $39.72 million, resulting in a stockholders’ deficit of $35.41 million and a working capital deficiency of $31.75 million. Management discloses that these conditions raise substantial doubt about the company’s ability to continue as a going concern and expects to rely on continued revenue growth plus additional debt and equity financings.
Ionic Ventures LLC and affiliated reporting persons report beneficial ownership of Biotricity Inc. common stock. They are deemed to beneficially own 3,241,770 shares of Common Stock, representing 9.9% of the class, based on 29,402,934 shares outstanding as of June 20, 2026.
The position consists of 194,550 shares of common stock and up to 3,047,220 Conversion Shares issuable from Series B Convertible Preferred Stock, subject to a 9.99% beneficial ownership Blocker and limits on the number of Conversion Notices under the Certificate of Designations. Ionic Management, Brendan O'Neil, and Keith Coulston are deemed to share voting and dispositive power over the same shares.
Biotricity Inc. is a Nevada-based medical technology company focused on remote biometric monitoring, particularly cardiac diagnostics and chronic care. Key offerings include FDA-cleared Bioflux mobile cardiac outpatient monitoring, Biocore and cellular Biocore Pro devices, plus consumer Bioheart monitors, the Biocare chronic-care platform and Biokit remote patient monitoring kits.
The company pursues an insourced, technology-as-a-service model, earning utilization-based recurring fees from cardiology offices, hospitals and IDTFs. It is expanding U.S. sales coverage and developing AI-driven cardiac analytics on major cloud platforms, while continuing to seek additional FDA clearances. Biotricity remains unprofitable, reporting an accumulated deficit of $142,570,243, and supports operations with a secured credit facility with borrowings of $14,45 million maturing in 2026 alongside ongoing R&D investment.
Biotricity, Inc. notified holders that its Board and consenting stockholders approved a 100:1 Reverse Stock Split, to be effected not later than ten days after FINRA notification (the "Effective Date"). The action was approved by consenting holders of 1,298,945 Series C Preferred shares representing 51,957,780 votes.
The Information Statement furnishes background on the split ratio, rounding policy for fractional shares (round up to the nearest whole share), expected accounting effects on stated capital and additional tax and procedural notes. The Board reserves discretion to abandon the Reverse Stock Split before implementation.
Biotricity, Inc. approved a 100:1 Reverse Stock Split. The Board and consenting stockholders holding 1,298,945 Series C Preferred shares (representing 51,957,780 votes, or 51.7%) executed a written consent dated May 28, 2026. The reverse split will become effective not later than ten days after notifying FINRA (the "Effective Date").
The reverse split will convert each one hundred (100) existing shares into one (1) new share, round fractional shares up to the nearest whole share, and will not change the number of authorized shares. The Information Statement was furnished to holders of record as of May 28, 2026.
Biotricity Inc. ownership update: Ionic Ventures, Ionic Management, Brendan O'Neil and Keith Coulston report beneficial ownership of 3,096,987 shares of common stock, representing 9.99% of the class based on February 11, 2026 outstanding shares. The position includes 532,757 directly or indirectly held common shares and conversion rights from 335 shares of Series B Convertible Preferred Stock that could produce additional "Conversion Shares" subject to a 9.99% Blocker in the Certificate of Designations.
The filing explains conversion mechanics: up to $2,250,000 of Preferred Stock could convert into 9,533,898 Conversion Shares at an $0.236 Alternate Conversion Price as of March 31, 2026, but the 9.99% blocker and limits on Conversion Notices constrain how many conversion shares are deemed beneficially owned for reporting. Shared voting and dispositive power over the reported shares is attributed to Ionic, Ionic Management, Mr. O'Neil and Mr. Coulston.
Biotricity Inc. entered exchange agreements on May 1, 2026 with holders of 14,144,325 common shares, options for 3,992,427 shares, and warrants for 1,436,216 shares. These securities were exchanged for 1,957,297 shares of newly created Series C Preferred Stock on a ten‑for‑one basis.
The company designated 2,100,000 Series C Preferred shares, each carrying 40 votes. After any equity financing raising at least $15 million, outstanding Series C will automatically convert into 59.6% of Biotricity’s common stock. If no such financing occurs by March 31, 2028, each Series C share may convert into 10 common shares.
Biotricity Inc. reported solid third-quarter fiscal 2026 results, with revenue rising 10.2% to $4 million from $3.6 million a year earlier. The company highlighted its third consecutive quarter of positive EBITDA and net operating income, reflecting growing adoption of its remote cardiac monitoring solutions.
Gross margin improved to 81.5% from 76.4%, helped by a larger recurring technology-fee base and AI-driven efficiencies. Net loss narrowed to $1.1 million, or $0.042 per share, compared with $1.3 million, or $0.054 per share. Management also pointed to strong customer retention above 90% and ongoing international expansion.